Similar articles

• Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

  Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S; National Israel Ovarian Cancer Study Group. Modan B, et al. N Engl J Med. 2001 Jul 26;345(4):235-40. doi: 10.1056/NEJM200107263450401. N Engl J Med. 2001. PMID: 11474660
• Oral contraceptives and hereditary ovarian cancer.

  de Souza RM, Lazzaron AR. de Souza RM, et al. N Engl J Med. 1999 Jan 7;340(1):59; author reply 60. doi: 10.1056/NEJM199901073400113. N Engl J Med. 1999. PMID: 9882211 No abstract available.
• Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

  Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Narod SA, et al. N Engl J Med. 1998 Aug 13;339(7):424-8. doi: 10.1056/NEJM199808133390702. N Engl J Med. 1998. PMID: 9700175
• Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

  Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Casey MJ, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
• Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.

  Kuschel B, Lux MP, Goecke TO, Beckmann MW. Kuschel B, et al. Eur J Cancer Prev. 2000 Jun;9(3):139-50. Eur J Cancer Prev. 2000. PMID: 10954253 Review.